>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
新辅助免疫检查点抑制剂用于非小细胞肺癌治疗的研究进展
作者:房进1  胡若愚2  薛涛2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属中大医院 胸心外科, 江苏 南京 210009
关键词:新辅助治疗 免疫检查点抑制剂 非小细胞肺癌 文献综述 
分类号:R734.2
出版年·卷·期(页码):2022·41·第二期(273-278)
摘要:

免疫检查点抑制剂(ICIs)通过阻断相应靶点,使T细胞维持其对肿瘤细胞的识别和杀伤,克服T细胞耗竭并重建自身免疫功能。新辅助ICIs治疗相较于辅助治疗有着独特优势,大量研究揭示了该方式提升治愈率的可能性。本综述旨在展现肺癌新辅助ICIs治疗的现状、应用前景以及面临的挑战。

参考文献:

[1] DETTERBECK F C,CHANSKY K,GROOME P,et al.The IASLC lung cancer staging project:methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming(eighth) edition of the TNM classification of lung cancer[J].J Thorac Oncol,2016,11(9):1433-1446.
[2] PLANCHARD D,POPAT S,KERR K,et al.Metastatic non-small cell lung cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29:v192-v237.
[3] O'DONNELL J S,HOEFSMIT E P,SMYTH M J,et al.The promise of neoadjuvant immunotherapy and surgery for cancer treatment[J].Clin Cancer Res,2019,25(19):5743-5751.
[4] RIBAS A,WOLCHOK J D.Cancer immunotherapy using checkpoint blockade[J].Science,2018,359(6382SI):1350.
[5] 高峰,洪亚珍,陈晨,等.癌症治疗的新兴免疫靶点及相关研究进展[J].中国肿瘤临床,2020,47(19):1001-1006.
[6] OHAEGBULAM K C,ASSAL A,LAZAR-MOLNAR E,et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21(1):24-33.
[7] 周彩存,王洁,步宏,等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版)[J].中国肺癌杂志,2020,23(2):65-76.
[8] SMOLLE M A,PRINZ F,CALIN G A,et al.Current concepts of non-coding RNA regulation of immune checkpoints in cancer[J].Mol Aspects Med,2019,70:117-126.
[9] BANNA G L,CANTALE O,BERSANELLI M,et al.Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm[J].Oncol Rev,2020,14(2):135-143.
[10] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
[11] RECK M,RODRÍGUEZ-ABREU D,ROBINSON A G,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375(19):1823-1833.
[12] MOK T,WU Y L,KUDABA I,et al.Pembrolizumab versus chemotherapy for previously untreated,PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):a randomized,open-label,controlled,phase 3 trial[J].Lancet,2019,393(10183):1819-1830.
[13] HIRSCH F R,SCAGLIOTTI G V,MULSHINE J L,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311.
[14] YANG C J,MCSHERRY F,MAYNE N R,et al.Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer[J].Ann Thorac Surg,2018,105(3):924-929.
[15] FORDE P M,CHAFT J E,SMITH K N,et al.Neoadjuvant PD-1 blockade in resectable lung cancer[J].N Engl J Med,2018,378(21):1976-1986.
[16] GAO S,LI N,GAO S,et al.Neoadjuvant PD-1 inhibitor(sintilimab) in NSCLC[J].J Thorac Oncol,2020,15(5):816-826.
[17] PROVENCIO M,NADAL E,INSA A,et al.Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer(NADIM):an open-label,multicenter,single-arm,phase 2 trial[J].Lancet Oncol,2020,21(11):1413-1422.
[18] CASCONE T,WILLIAM W N,WEISSFERDT A,et al.Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer:the phase 2 randomized NEOSTAR trial[J].Nat Med,2021,27(3):504-514.
[19] PETERS S,KIM A W,SOLOMON B,et al.IMpower030:Phase Ⅲ study evaluating neoadjuvant treatment of resectable stage Ⅱ-ⅢB non-small cell lung cancer(NSCLC) with atezolizumab(atezo) plus chemotherapy[J].Ann Oncol,2019,302:30.
[20] FELIP E,BRAHMER J,BRODERICK S,et al.Checkmate 816:A phase 3 trial of neoadjuvant nivolumab plus ipilimumab or chemotherapy vs chemotherapy in early-stage NSCLC[J].J Thorac Oncol,2018,13S(10):S831-S832.
[21] TSUBOI M,LUFT A,URSOL G,et al.Perioperative pembrolizumab plus platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer:the phase Ⅲ Keynote-671 study[J].Ann Oncol,2020,314:S801-S802.
[22] HEYMACH J,TAUBE J,MITSUDOMI T,et al.The AEGEAN phase 3 trial of neoadjuvant/adjuvant durvalumab in patients with resectable stage Ⅱ/Ⅲ NSCLC[J].J Thorac Oncol,2019,14S(10):S625-S626.
[23] CASCONE T,PROVENCIO M,SEPESI B,et al.Checkmate 77T:a phase Ⅲ trial of neoadjuvant nivolumab(nivo) plus chemotherapy(chemo) followed by adjuvant nivo in resectable early-stage NSCLC[J].J Clin Oncol,2020,38S(15):TPS9076.
[24] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2019版)[J].中华肿瘤杂志,2020,42(4):257-287.
[25] SCHUCHERT M J,NORMOLLE D P,AWAIS O,et al.Factors influencing recurrence following anatomic lung resection for clinical stage Ⅰ non-small cell lung cancer[J].Lung Cancer,2019,128:145-151.
[26] GRAY J E,VILLEGAS A,DANIEL D,et al.Three-year overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC—update from PACIFIC[J].J Thorac Oncol,2020,15(2):288-293.
[27] ZHOU C,CHEN G,HUANG Y,et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer(CameL):a randomized,open-label,multicenter,phase 3 trial[J].Lancet Respir Med,2021,9(3):305-314.
[28] CHAFT J E,HELLMANN M D,VELEZ M J,et al.Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors[J].Ann Thorac Surg,2017,104(3):e217-e218.
[29] OH M,DAVIS A,LENTZ R,et al.The role of neoadjuvant chemo-immunotherapy in unresectable non-small cell lung cancer[J].J Thorac Oncol,2019,14S(10):S947-S948.
[30] CHEN T,NING J,CAMPISI A,et al.Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC:a retrospective study[J].Ann Thorac Surg,2022,113(3):993-999.
[31] BOTT M J,YANG S C,PARK B J,et al.Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer[J].J Thorac Cardiovasc Surg,2019,158(1):269-276.
[32] RUSCH V W,CHAFT J E,JOHNSON B,et al.Neoadjuvant atezolizumab in resectable non-small cell lung cancer(NSCLC):initial results from a multicenter study(LCMC3)[J].J Clin Oncol,2018,36S(15):8541.
[33] SUZUKI K,SAJI H,AOKAGE K,et al.Comparison of pulmonary segmentectomy and lobectomy:safety results of a randomized trial[J].J Thorac Cardiovasc Surg,2019,158(3):895-907.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 343117 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364